News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Safety Issues to Delay Novartis International AG (NVS)'s Galvus


11/6/2007 6:52:48 AM

ZURICH (Reuters) - Novartis AG has found new liver safety problems with high doses of its diabetes medicine Galvus, delaying the key drug's path to market in Europe and raising further questions over its future.

Read at Reuters

comments powered by Disqus
Reuters
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES